Kutyifa Valentina, Beck Christopher, Brown Mary W, Cannom David, Daubert James, Estes Mark, Greenberg Henry, Goldenberg Ilan, Hammes Stephen, Huang David, Klein Helmut, Knops Reinoud, Kosiborod Mikhail, Poole Jeanne, Schuger Claudio, Singh Jagmeet P, Solomon Scott, Wilber David, Zareba Wojciech, Moss Arthur J
Heart Research Follow-up Program of the Cardiology Division of the Department of Medicine, University of Rochester Medical Center, Rochester, NY.
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
Am Heart J. 2017 Jul;189:158-166. doi: 10.1016/j.ahj.2017.04.014. Epub 2017 May 4.
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
患有糖尿病、既往有心肌梗死、年龄较大且左心室射血分数相对保留的患者，仍有心脏性猝死风险，而皮下植入式心律转复除颤器可能对其有效，且风险效益比良好。已启动的MADIT S-ICD研究旨在检验以下假设：心肌梗死后射血分数相对保留在36%-50%的糖尿病患者，将从皮下植入式心律转复除颤器中获得生存益处。
